Chai Discovery, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chai Discovery, Inc. - overview
Established
2024
Location
San Francisco, CA, US
Primary Industry
Healthcare IT
About
Based in New York, US, and founded in 2024 by co-founders Joshua Meier (CEO) and Jack Dent, Chai Discovery, Inc. Chai Discovery, Inc. operates as a provider of an AI-based platform that delivers advanced molecular structure prediction models to research institutions and pharmaceutical companies. In December 2025, Chai Discovery, Inc.
raised USD 130 million in series B funding co-led by new investors Oak HC/FT and General Catalyst Partners, with participation from returning investors Dimension, Menlo Ventures, NEO, OpenAI, L. L. C. , SV Angel, Thrive Capital, and Yosemite Management.
Other new investors Emerson Collective, Glade Brook Capital Partners, other unspecified investors and individual investors also participated in the round. The company provides an artificial intelligence platform that offers advanced molecular structure prediction to biotech firms. The platform services include prediction of proteins, small molecules, DNA, RNA, and covalent modifications. Moreover, the firm offers solutions such as the Chai-1 model for both commercial and non-commercial use, technical reports, model weights, and inference code for research purposes.
Additionally, the firm also provides web-based access and GitHub repository support for the Chai-1 model.
Current Investors
Dimension Capital Management, Thrive, OpenAI
Primary Industry
Healthcare IT
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Scientific Software
Website
www.chaidiscovery.com
Verticals
Artificial Intelligence, Artificial Intelligence, Big Data, HealthTech, Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.